Cynthia Fisher consults to CEOs, investment firms, and serves on corporate boards as a Director. She was the co-founder and President of ViaCell, Inc., a cord blood stem cell banking and cellular medicines company developing human cellular therapies. ViaCell went public in 2005 (VIAC). ViaCell was recently acquired by PerkinElmer, Inc. for $300 million, primarily for the cord blood stem cell banking service, ViaCord, Inc, which Cynthia founded in 1993. She served as President and CEO of ViaCord for the first seven years prior to its merger with ViaCell. She subsequently founded and served as CEO of BioMed 20/20 Technologies, a biotechnology and medical information company.
Earlier in her career, she was the Marketing Manager for the Blood Bank Division of Haemonetics Corporation. She started her career with IBM Corporation in sales and marketing account management. Cynthia served as Chairman of the Board of Directors of the Massachusetts Biotechnology Council. She currently serves on the Board of Cambria Biosciences. She is a member of the National Advisory Council of Harvard Medical School for Systems and Cell Biology.
She formerly served as Trustee of Ursinus College for three terms and on the boards of ViaCell, Inc., ViaCord, Inc., and various family-owned businesses. She received an Honorary Doctorate of Science from Ursinus College, an MBA from Harvard University, and a BS in Biophysics from Ursinus College